2,414 results on '"Benedetti, Fabrizio"'
Search Results
102. Contributors
103. Placebo Effect
104. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma.
105. Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor–Associated Periodic Syndrome: Results From a Phase III Trial.
106. Placebo and Nocebo Effects: An Introduction to Psychological and Biological Mechanisms
107. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study
108. The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
109. The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)
110. Characterization of AR-CGD female patient with a novel homozygous deletion in CYBC1 gene presenting with unusual clinical phenotype
111. Vasculiti facili e difficili: cosa deve sapere e saper fare un pediatra
112. Persistently active interferon‐γ pathway and expansion of T‐bet + B cells in a subset of patients with childhood‐onset systemic lupus erythematosus
113. Case Report: Interindividual variability and possible role of heterozygous variants in a family with deficiency of adenosine deaminase 2: are all heterozygous born equals?
114. Microbiota transplant to control inflammation in a patient with NLRC4 gain-of-function–induced disease
115. Sirolimus as a possible treatment in cleavage-resistant RIPK1-induced autoinflammatory syndrome
116. Can Dissipative Properties of Single Molecules Be Extracted from a Force Spectroscopy Experiment?
117. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects
118. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation
119. Placebo Effect
120. Introducing Supercoiling into Models of Chromosome Structure
121. The Special Case of High-Altitude Headache
122. Interleukin-18 in pediatric rheumatic diseases
123. Magnitude, response, and psychological determinants of placebo effects in chronic low-back pain: a randomised, double-blinded, controlled trial
124. The pharmacology of placebos
125. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?
126. An unusual presentation of purine nucleoside phosphorylase deficiency mimicking systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome
127. The 4th NextGen Therapies for SJIA and MAS: part 1 the elephant in the room: diagnostic/classification criteria for systemic juvenile idiopathic arthritis and adult-onset still's disease
128. The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)
129. The 4th NextGen therapies for SJIA and MAS: part 3 clinical trials in refractory SJIA: historic controls as an alternative to a withdrawal design study.
130. Placebo and nocebo responses in painful diabetic neuropathy: systematic review and meta-analysis.
131. Placebo and nocebo responses in painful diabetic neuropathy: systematic review and meta-analysis (P9-6.002)
132. Supplementary Table from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
133. Supplementary Figure from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
134. Supplementary Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
135. Data from Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy
136. P090 Protocol for the two-cohort, open-label, single-arm EMERALD study of emapalumab, an anti-interferon gamma monoclonal antibody, in patients with macrophage activation syndrome in rheumatic diseases
137. Efficacy and safety of emapalumab in macrophage activation syndrome
138. The mature/pro nerve growth factor ratio is decreased in the brain of diabetic rats: Analysis by ELISA methods
139. Functional and Morphological Improvement of Dystrophic Muscle by Interleukin 6 Receptor Blockade
140. Correction to: The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
141. Why We should Assess Patients’ Expectations in Clinical Trials
142. Placebo Analgesia and Descending Opioid Modulation
143. Pain and the Placebo/Nocebo Effect
144. Sjogren Syndrome, Raynaud’s Phenomenon, Overlap Syndromes
145. Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma
146. Efficacy and safety of emapalumab in macrophage activation syndrome
147. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions
148. Pediatric recurrent pericarditis: Appropriateness of the standard of care and response to IL-1 blockade
149. Placebo Effects: From the Neurobiological Paradigm to Translational Implications
150. Characterization of the thalamic–subthalamic circuit involved in the placebo response through single-neuron recording in Parkinson patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.